Some of the most commercially significant opportunities in animal health are in categories that barely existed five years ago. But building a new therapeutic category is fundamentally different from launching a product into an established one. There are no existing treatment protocols, no established referral pathways, and often no clear regulatory template. This session will explore what it takes to build a category from scratch: the science, the regulatory strategy, the commercial model, and the investment thesis.
Celine Halioua
Celine Halioua is the Founder and CEO of Loyal, a clinical-stage animal health company
developing the first longevity drugs for dogs. Since founding Loyal in 2019, she has raised over $150M and has led the company through several historic regulatory milestones, including earning what is believed to be the first- and second-ever acceptances from the FDA that a drugcould be effectively developed for lifespan extension.
Prior to Loyal, Celine was Chief of Staff at the Longevity Fund and pursued a DPhil in the
economics of healthcare at Oxford University. She holds a B.S. in neuroscience from the
University of Texas at Austin.